LOGIN  |  REGISTER
C4 Therapeutics

embecta to Participate in Investor Events

May 01, 2024 | Last Trade: US$11.46 0.61 -5.05

PARSIPPANY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that management will participate in the following investor events:

2024 BofA Securities Healthcare Conference

  • Management will host a fireside session on Thursday, May 16, 2024, at 10:00 a.m. Pacific Time (PT) at the Encore Hotel in Las Vegas. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at https://investors.embecta.com.

2024 Jefferies Global Healthcare Conference

  • Management will host a fireside session on Wednesday, June 5, 2024, at 5:30 p.m. Eastern Time (ET) at the Marriott Marquis in New York. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at https://investors.embecta.com.

2024 Truist Securities MedTech Conference

  • Management will host one-on-one investor meetings on Tuesday, June 18, 2024, at the InterContinental Hotel in Boston.

2024 Stifel’s Inaugural ADA Diabetes Tech Summit

  • Management will host a fireside session on Friday, June 21, 2024, in Orlando.

About embecta 

embecta is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.

Contacts:

MediaInvestors 
Christian GlazarPravesh Khandelwal
Sr. Director, Corporate CommunicationsVP, Head of Investor Relations
908-821-6922551-264-6547
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB